Confirming its decision to not cut the National Health Service, the UK’s Coalition government says it has made its choice: to deliver better outcomes for patients: earlier diagnosis; better and faster treatment - and lives saved.
A Department of Health statement noted that the government is reforming the NHS “to make every penny count for patients. But we are also taking the action needed - right across the board - to ensure our NHS is equipped to meet this challenge.”
Health Secretary Andrew Lansley said: “I want the NHS to deliver cancer survival rates comparable to the best in the world.” He confirmed a previous coalition pledge of £50 million ($79.7 million) in cancer drugs funding. This will help patients get access to drugs that extend life or improve quality of life and are more readily available in the rest of Europe. Because of decisions made by the drugs watchdog the National Institute of Health and Clinical Excellence (NICE), UK patients have been denied a number of new oncology drugs that are available in other European countries.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze